Reduction of iron stores and clinical outcomes in peripheral arterial disease: Outcome comparisons in smokers and non-smokers

Vascular

Volumn 21, Issue 4, 2013, Pages 233-241

  DePalma, Ralph G ^a   Zacharski, Leo R ^b   Chow, Bruce K ^c   Shamayeva, Galina ^c   Hayes, Virginia W ^d  

^a DEPARTMENT OF VETERANS AFFAIRS   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^d Sierra Nevada Health Care System   (United States)

Author keywords

Ferritin; Iron reduction; Peripheral arterial disease; Phlebotomy; Smoking

Indexed keywords

FERRITIN; FIBRINOGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRON;

ADULT; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; COMPARATIVE STUDY; CONTROLLED STUDY; DEATH; FOLLOW UP; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHLEBOTOMY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SMOKING; PROSPECTIVE STUDY;

FERRITINS; HUMANS; IRON; PERIPHERAL ARTERIAL DISEASE; PHLEBOTOMY; PROSPECTIVE STUDIES;

EID: 84879894366     PISSN: 17085381     EISSN: 1708539X     Source Type: Journal    
DOI: 10.1177/1708538113478776     Document Type: Article

References (40)

1. Zacharski LR, Chow BK, Howes PS, et al. Reduction of iron stores and cardiovascular outcomes in patients with peripheral arterial disease: a randomized controlled trial. JAMA 2007;297:603-10.
2. Zacharski LR, Shamayeva G, Chow BK. Effect of controlled reduction of body iron stores on clinical outcomes in peripheral arterial disease. Am Heart J 2011;162:949-57.
3. Fraser IS, Warner P, Marantos PA. Estimating menstrual blood loss in women with normal and excessive menstrual fluid volume. Obstet Gynecol 2001;98:806-14.
4. Zacharski LR, Ornstein DL, Woloshin S, Schwartz LM. Association of age, sex, and race with body iron stores in adults: analysis of NHANES III data. Am Heart J 2000;140:98-104.
5. Sullivan JL. Iron and the sex difference in heart disease risk. Lancet 1981;1:1293-4.
6. Zacharski LR, Howes PS, Shamayeva G, et al. Decreased cancer risk after iron reduction in patients with peripheral arterial disease: results from a randomized trial. J Natl Cancer Inst 2008; 100:996-1002.
7. DePalma RG, Hayes VW, Cafferata HT, et al. Cytokine signatures in atherosclerotic claudicants. J Surg Res 2003;15:215-21.
8. DePalma RG, Hayes VW, May PE, et al. Statins and biomarkers in claudicants with peripheral vascular disease. Vascular 2006;14:193-20.
9. DePalma RG, Hayes VW, Chow BK, Shamayeva G, May PE, Zacharski LR. Ferritin levels, inflammatory biomarkers, and mortality in peripheral arterial disease: a substudy of the Iron (Fe) and Atherosclerosis Study (FeAST) Trial. J Vasc Surg 2010;51:1498.
10. Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975;31:103-15.
11. Zacharski LR, Chow BK, Howes PS, et al. Implementation of an iron reduction protocol in patients with peripheral vascular disease: VA cooperative study no. 410: the Iron (Fe) and Atherosclerosis Study (FeAST). Am Heart J 2004;148:386-92.
12. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958;53:457-81.
13. Cox DR. Regression models and life-tables. J R Stat Soc (B) 1972;34:187-220.
14. DePalma RG, Hayes VW. Atherosclerosis: risk factors and medical management. In: White RA, Hollier LA, eds. Vascular Surgery: Basic Science and Clinical Correlations. Malden, MA: Blackwell Futura, 2005:441-53.
15. Hawkins LH, Cole PV, Harris JRW. Smoking habits and blood carbon monoxide levels. Environ Res 1976;11:310-8.
16. Balukamar P, Kaur J. Is nicotine a key player or spectator in the induction and progression of cardiovascular disorders? Pharmacol Res 2009;60:361-8.
17. Ghio AJ, Hilborn ED, Stonehuemer JG, et al. Particulate matter in cigarette smoke alters iron homeostasis to produce a biological outcome. Am J Respir Crit Care Med 2008;178:1130-8.
18. Garrison RJ, Kannel WB, Feinlab M, et al. Cigarette smoking and HDL cholesterol: the Framingham Offspring Study. Atherosclerosis 1978;30:17-25.
19. Hu FB. The iron-heart hypothesis; search for the ironclad evidence. JAMA 2007;297:639-41.
20. Sullivan JL, Mascitelli L. Current status of the iron hypothesis of cardiovascular disease. Recenti Prog Med 2007;98:373-7.
21. Lieb M, Palm U, Hock B, Schwarz M, et al. Effects of alcohol consumption on iron metabolism. Am J Drug Alcohol Abuse 2011;37:68-73.
22. Ford ES, Cogswell ME. Diabetes and serum ferritin concentration among U.S. adults. Diabetes Care 1999;22:1978-83.
23. Piperno A, Trombini P, Gelosa M, et al. Increased serum ferritin is common in men with essential hypertension. J Hypertens 2002;20:1513-8.
24. Iwasaki T, Nakajima A, Yoneda M, et al. Serum ferritin is associated with visceral fat area and subcutaneous fat area. Diabetes Care 2005;10:2486-91.
25. Casanova-Esteban P, Guiral N, Andrés E, et al. Effect of phlebotomy on lipid metabolism in subjects with hereditary hemochromatosis. Metabolism. 2011;60:830-4.
26. Sullivan JL. Regarding 'Statins, heme oxygenase-1, iron, and atherosclerosis'. J Vasc Surg 2010;52:536-7.
27. DePalma RG, Hayes VW, Chow BK, et al. Reply to Sullivan JL re iron reduction and heme oxidase. J Vasc Surg 2010;52:537.
28. Abluwalia N, Genoux A, Ferrieres J, et al. Iron status is associated with carotid plaques in middle aged adults. J Nutr 2010; 140:812-6.
29. Kell DB. Iron behaving badly: inappropriate iron chelation as a major contributor to the etiology of vascular and other progressive inflammatory and degenerative diseases. BMC Med Genom 2009;2:2 doi: 10.1186/1755-8794-2-2. See http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2672098/?tool=pubmed (last checked 12 July 2011)
30. Veiner HL, Levy AP. Haptoglobin genotype and the iron hypothesis of atherosclerosis. Atherosclerosis 2011;216:17-8.
31. Ridker PM, Cushman M, Stampfer M, et al. Plasma concentration of C reactive protein and risk of developing peripheral vascular disease. Circulation 1998;10:425-8.
32. Engstrom G, Site-Flondell D, Lindblad B, et al. Risk of treatment of peripheral arterial disease is related to inflammation-sensitive plasma proteins: a prospective cohort study. J Vasc Surg 2004;40:1101-5.
33. Lindstrom D. Comments regarding 'Measuring effects of smoking cessation in patients with vascular disease'. Invited commentary. J Vasc and Endovasc Surg 2010;40:361-4.
34. Patterson CC, Smith AE, Yarnell JW, et al. The associations of interleukin-6 (IL6) and downstream inflammatory markers with risk of cardiovascular disease: the Caerphilly Study. Atherosclerosis 2010;209:551-7.
35. Salonen JT, Korpela H, Nyyssonen K, et al. Lowering of body iron stores by blood letting and oxidation resistance of serum proteins: a randomized cross over trial in male smokers. J Intern Med 1995;237:161-8.
36. Faccini FS, Saylor KL. Effect if iron depletion on cardiovascular risk factors: studies in carbohydrate-intolerant patients. Ann N Y Acad Sci 2002;967:342-51.
37. Martinez JA, Guerra CC, Nery LE, et al. Iron stores and coagulation parameters in patients with hypoxemic polycythemia secondary to chronic obstructive pulmonary disease: the effect of phlebotomies. San Paulo Med J 1997;115:1395-402.
38. Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: fifty years' observations on male British doctors. BMJ 2004;328:1519-28.
39. Friedman LM, Furberg CD, DeMetz DL. Fundamentals of Clinical Trials. 4th edn. Chapter 2 Ethical Issues. New York: Springer Scientific and Business Media LLC, 2010;486-9.
40. Unverdorben M, von Holt K, Winkleman BR. Smoking and atherosclerotic cardiovascular disease: part II: role of cigarette smoking in cardiovascular disease development. Biomark Med 2009;3:617-53